News Articles

New patient survey reveals: For people with atrial fibrillation, reversal of their blood thinning treatment is highly... INGELHEIM, Germany -Wednesday 27 June 2018

89% of surveyed patients with atrial fibrillation (AF) are aware of potential complications which may arise due to their blood thinning treatment in the event of an emergency The majority (83%) considered it important to know about a medication which could stop the blood thinning...

Systemic Sclerosis World Congress: Inspirational Patient Stories Reveal the Challenging Realities of Living with... -Friday 16 February 2018  

'More Than Scleroderma: The Inside Story' provides real-life stories and education about the life-threatening disease New and truly inspiring patient stories are revealed Help raise awareness of this little-known disease by visiting www.morethanscleroderma.com “I’ve learned how to...

Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To... -Monday 20 November 2017

opnME.com provides scientists with many best-in-class tool molecules supported by comprehensive data packages on one centralized platform for researchers to use The platform offers direct access to molecules for independent research as well as other molecules for partnering with Boehringer...

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery... -Tuesday 14 November 2017  

Empagliflozin (marketed as Jardiance®) reduced the risk of cardiovascular death by 43 percent versus placebo in patients with type 2 diabetes and peripheral artery disease1 In a population at high risk for amputations, no increased risk in lower-limb amputation was observed with...

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of... -Monday 13 November 2017

(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation for Cyltezo® a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases in adults and children.* “Cyltezo® is the first biosimilar from...

Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including... -Thursday 2 November 2017

Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an undisclosed target The collaboration will investigate a new therapeutic approach that enables addressing previously inaccessible drug targets to...

IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’ -Monday 18 September 2017      

(BUSINESS WIRE)-- IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be...

CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in... -Monday 18 September 2017  

The CHMP of the EMA has issued a positive opinion for an update of the Summary of Product Characteristics (SmPC) for Pradaxa® (dabigatran etexilate) The CHMP recommends to include data showing that catheter ablation can be conducted in patients on 150 mg twice daily Pradaxa®,...

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO® -Friday 15 September 2017

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cyltezo® (adalimumab biosimilar) for the treatment of multiple chronic inflammatory diseases Recommendation based on extensive analytical, pharmacological, non...

Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple... -Sunday 27 August 2017  

(BUSINESS WIRE)-- The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary intervention (PCI) and stent placement: results showed significantly lower...

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and... -Thursday 27 July 2017

First patient enrolled into VOLTAIRE-X; an interchangeability study designed to assess whether BI 695501 is interchangeable with Humira®1 First study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate BI 695501 is currently under review by...

People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey  -Monday 24 July 2017

• 61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1 • Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 • Healthcare teams emphasise the need of a strong support network and...

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa®... -Tuesday 11 July 2017  

Complete data set from 503 patients show that Praxbind® (idarucizumab) led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate) in emergency settings1 Final results from RE-VERSE AD™ were presented as a late-breaker at the ISTH...

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients -Wednesday 21 June 2017  

Findings from global observational study, GLORIA™-AF, reinforce the high need for screening programmes1 Data presented at EHRA-EUROPACE CARDIOSTIM 2017 and selected for Highlights Session (abstract 1669)1 (BUSINESS WIRE)-- Boehringer Ingelheim today announced findings from...

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017 -Monday 5 June 2017

(BUSINESS WIRE)-- Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomised, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO). Nintedanib*,...

Boehringer Ingelheim: A New World Leader in Animal Health -Wednesday 5 April 2017

(BUSINESS WIRE)-- Three months after acquiring animal health leader Merial in a strategic transaction with Sanofi, Boehringer Ingelheim revealed its ambition to compete for industry leadership worldwide in animal health. Boehringer Ingelheim management discussed the importance of its animal...

First dedicated outcome trials of empagliflozin in chronic heart failure initiated -Friday 17 March 2017  

EMPEROR HF clinical trial programme will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes Heart failure (HF) affects 26 million people worldwide and is associated with high morbidity and...

Jardiance® (empagliflozin) becomes first type 2 diabetes medicine in the EU to include cardiovascular... -Thursday 26 January 2017  

This is the first time the European Commission approved the use of a diabetes treatment for its effect on both blood sugar control and cardiovascular (CV) events The CV data incorporated into the updated label are from the EMPA-REG OUTCOME® trial, which showed Jardiance® reduced the risk...

Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017 -Monday 2 January 2017  

(BUSINESS WIRE)-- Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi’s animal health business (Merial) and Boehringer Ingelheim’s consumer healthcare (CHC) business, has been successfully closed in...

CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death -Friday 16 December 2016  

In the EMPA-REG OUTCOME® trial Jardiance® reduced the risk of cardiovascular (CV) death by 38 percent vs placebo in patients with type 2 diabetes (T2D) and established CV disease when added to standard of care The Committee for Medicinal Products for Human Use (CHMP) recommends to...